IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.